Primary Site >> Liver Cancer
Gene >> SLC22A1
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
|
Ref: Molecular determinants in the transport of a bile acid-derived diagnostic agent in tumoral and nontumoral cell lines of human liver. PMID: 16895978 |
Ref: DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. PMID: 22196450 |
Ref: Drug transporter regulation in tumors by DNA methylation. PMID: 22293136 Ref: Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. PMID: 22439694 Ref: No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors. PMID: 22524153 |
Ref: Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites. PMID: 23482500 Ref: Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. PMID: 23532667 Ref: Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology. PMID: 23984399 |
Ref: Differential expression of drug uptake and efflux transporters in Japanese patients with hepatocellular carcinoma. PMID: 25231932 |
Ref: [Low expression of SLC22A1 is associated with a poor prognosis of hepatocellular carcinoma: analysis of 303 patients]. PMID: 26547334 |
Ref: Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment. PMID: 26872727 Ref: Drug Transporter Expression and Activity in Human Hepatoma HuH-7 Cells. PMID: 28036031 |
Ref: The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma. PMID: 28178663 Ref: Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228). PMID: 28817838 Ref: Screening the key genes of hepatocellular adenoma via microarray analysis of DNA expression and methylation profiles. PMID: 28943905 |